---
title: "Exploring the evidence for use of cefiderocol as part of combination therapies: a systematic review of *in vitro*, *in vivo*, and clinical studies"
subtitle: "Supplementary material"
author:
  - name: Marco Meroi
    equal-contributor: true
    affiliation:
      - ref: verona
  - name: Juan Antonio del Castillo Polo
    equal-contributor: true
    affiliation:
      - ref: spain
  - name: Rebecca Scardellato
    affiliation:
      - ref: verona
  - name: Alessandra Nazeri
    affiliation:
      - ref: verona
  - name: Alessia Savoldi
    orcid: 0000-0003-1873-5323
    affiliation:
      - ref: verona
  - name: Renata Da Costa
    affiliation:
      - ref: gardp
  - name: Laura Piddock
    affiliation:
      - ref: gardp
  - name: Jennifer Cohn
    affiliation:
      - ref: gardp
  - name: Evelina Tacconelli
    orcid: 0000-0003-2010-4977
    affiliation:
      - ref: verona
  - name: Matteo Morra
    corresponding: true
    orcid: 0000-0002-1684-0261
    email: matteo.morra@univr.it
    affiliation:
      - ref: verona
  - name: Elda Righi
    affiliation:
      - ref: verona
affiliations:
  
  - id: verona
    name: "Division of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy"
  - id: spain
    name: "Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain"
  - id: gardp
    name: "Global Antibiotic Research and Development Partnership (GARDP), Geneva, Switzerland"
bibliography: bibliography.bib
csl: Utils/elsevier-vancouver.csl

filters:
  - authors-block
  - landscape
    
format:
  wordcount-docx: default
  pdf:
    keep-tex: true
    toc: true
    toc-depth: 3

# format:
#   elsevier-pdf:
#     keep-tex: true
#     journal:
#       formatting: review
#       model: 1p
#       cite-style: number
---

# Study characteristics

The characteristics of the included studies are summarized in **Table 1** for *in vitro* and *in vivo* studies and in **Table 2** for clinical studies.

::: landscape
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| **Author, year**                               | **Molecules**                         | **Methods**                                            | **Isolates**                                                                         | **Synergy**                                                                                                 | **Result**                                             |
+:===============================================+:======================================+:=======================================================+:=====================================================================================+:============================================================================================================+:======================================================:+
| Tsuji, 2016 [@tsuji2016]                       | MER, AMK, and COL                     | BMD MIC                                                | 41 EB, 20 *Pa*, and 21 *Ab* resistant to meropenem                                   | Synergy for MER (11% *Pa*, 26% EB and 43% *Ab*)                                                             | ![](images/green_synergy.png){width="35" height="35"}  |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
|                                                | MER, AMK, and CIP                     | Checkerboard and time-kill                             | 1 FDC-R KPC-*Kp*, 1 VIM-10-*Pa, and* 1 FDC-R MDR-*Ab*                                | Synergy for MER in *Kp* and AMK in *Ab*                                                                     | ![](images/green_synergy.png){width="35" height="35"}  |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Palombo, 2023 [@palombo2023]                   | P–T, FOS, A–S, CZA, MEV, and IMR      | Gradient diffusion strip crossing                      | FDC-R: 1 *Kp* and 1 *Ab*                                                             | No synergy for P/T, MEV, IMR                                                                                | ![](images/yellow_synergy.png){width="34" height="35"} |
|                                                |                                       |                                                        |                                                                                      |                                                                                                             |                                                        |
|                                                |                                       |                                                        | FDC-S: 1 *Kp*, 1 *Ab*, and 2 *Pa*                                                    | FDC-R: synergy for FOS (n=2) and CZA in 1 *Kp;*                                                             |                                                        |
|                                                |                                       |                                                        |                                                                                      |                                                                                                             |                                                        |
|                                                |                                       |                                                        |                                                                                      | FDC-S: synergy for CZA in 1 *Pa* and A-S in 1 *Pa*                                                          |                                                        |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Kohira, 2020 [@kohira2020]                     | AVI                                   | BMD MIC                                                | 33 non-NDM-EB, *Ab*, and *Pa*                                                        | ≥8-fold MIC decrease in 32/33                                                                               | ![](images/green_synergy.png){width="35" height="35"}  |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Le Terrier, 2024 [@leterrier2024]              | ZID, TAN, NAC, AVI, REL, VAB          | BMD MIC                                                | 67 EB, 9 *Pa* and 11 *Ab*                                                            | EB and *Pa*: FDC+ZID showed the highest susceptibility rate, other combinations had lower rates             | ![](images/green_synergy.png){width="35" height="35"}  |
|                                                |                                       |                                                        |                                                                                      |                                                                                                             |                                                        |
|                                                |                                       |                                                        |                                                                                      | *Ab*: FDC+ZID, AVI, TAN or REL had susceptibility rates \>90% (FDC alone 9.1%)                              |                                                        |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Xu, 2025 [@xu2025]                             | ZID                                   | Checkerboard                                           | 14 FDC-R-EB + FDC-S-*Ab*                                                             | ZID restored and even enhanced FDC antibacterial activity                                                   | ![](images/green_synergy.png){width="35" height="35"}  |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
|                                                |                                       | Time-kill                                              | 8 FDC-R-EB + FDC-S-*Ab*                                                              | FDC+ZID inhibited the growth of all strains (FDC did not achieve it)                                        | ![](images/green_synergy.png){width="35" height="35"}  |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
|                                                |                                       | Cell infection model                                   | 1 FDC-R-*Ent. cloacae*                                                               | FDC+ZID: significant reduction in the number of viable intracellular bacteria                               | ![](images/green_synergy.png){width="35" height="35"}  |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Hara, 2024 [@hara2025]                         | XER                                   | BMD MIC                                                | 160 FDC-R and S-*Ab*                                                                 | XER significantly improved FDC activity                                                                     | ![](images/green_synergy.png){width="35" height="35"}  |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Hara, 2024 [@hara2025a]                        | XER                                   | BMD MIC                                                | 165 EB (139 CRE)                                                                     | XER significantly improved FDC activity                                                                     | ![](images/green_synergy.png){width="35" height="35"}  |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Yamano, 2019 [@yamano2019]                     | CZA, TOL-TAZ, and MER                 | BMD MIC, checkerboard, time-kill, chemostat            | 9 EB (5 NDM), and 28 *Ab* (25 PER), all FDC-R                                        | CZA, TOL-TAZ and MER synergic against non-NDM isolates (including PER-producing *Ab)*                       | ![](images/green_synergy.png){width="35" height="35"}  |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Lewis, 2024 [@lewis2024]                       | AVI, SUL, TAZ                         | Time-kill                                              | 2 *Kp*, 2 *Pa* and 2 *Ab* (FDC-R and S)                                              | SUL enhanced FDC activity in all isolates                                                                   | ![](images/green_synergy.png){height="35"}             |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Giordano, 2024 [@giordano2024]                 | Glycine                               | Checkerboard                                           | 5 NDM-*Kp* + 5 *Ab* (all FDC-R)                                                      | Positive interaction but no synergy                                                                         | ![](images/red_synergy.png){width="35" height="35"}    |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Abdul-Mutakabbir, 2021 [@abdul-mutakabbir2020] | MER, AMK, TGC, MIN, SUL, CZA, and COL | Time-kill                                              | 6 FDC-R *Ab*                                                                         | No synergy for CZA and COL (in COL-R). Synergy for the other antibiotics                                    | ![](images/yellow_synergy.png){width="35" height="35"} |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Ni, 2022 [@ni2022]                             | TGC, COL, and MER                     | Checkerboard                                           | 123 CRAB (44 FDC-R and 79 S)                                                         | S: synergy for TGC (85%)                                                                                    | ![](images/green_synergy.png){width="35" height="35"}  |
|                                                |                                       |                                                        |                                                                                      |                                                                                                             |                                                        |
|                                                |                                       |                                                        |                                                                                      | R: synergy for TGC (91%), COL (48%), and MER (80%)                                                          |                                                        |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
|                                                |                                       | Time-kill                                              | 21 CRAB (14 FDC-R and 7 S)                                                           | S: synergy for TGC (100%)                                                                                   | ![](images/green_synergy.png){width="35" height="35"}  |
|                                                |                                       |                                                        |                                                                                      |                                                                                                             |                                                        |
|                                                |                                       |                                                        |                                                                                      | R: synergy for TGC and COL (100%)                                                                           |                                                        |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
|                                                | TGC and COL                           | *In vivo* model                                        | 4 CRAB (2-FDC-R and 2 S)                                                             | S: FDC-TGC increased survival                                                                               | ![](images/green_synergy.png){width="35" height="35"}  |
|                                                |                                       |                                                        |                                                                                      |                                                                                                             |                                                        |
|                                                |                                       |                                                        |                                                                                      | R: FDC-TGC and FDC-COL increased survival                                                                   |                                                        |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Yin, 2024 [@yin2025]                           | TET analogues (MIN, TIG, ERA, OMA)    | Checkerboard                                           | 48 FDC-S CRAB                                                                        | Synergy in 35.4% MIN, 33.3% TIG, 50.0% ERA and 37.5% OMA                                                    | ![](images/green_synergy.png){width="35" height="35"}  |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
|                                                |                                       | Time-kill                                              | 10 FDC-S CRAB                                                                        | Synergistic effects in most isolates                                                                        | ![](images/green_synergy.png){width="35" height="35"}  |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
|                                                |                                       | *In vivo* model                                        | 2 FDC-S CRAB                                                                         | FDC+ERA reduced nearly 2 log~10~ CFU/thigh                                                                  | ![](images/green_synergy.png){width="35" height="35"}  |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Stolfa, 2021 [@stolfa2021]                     | COL, TGC, and FOS                     | Gradient diffusion strip crossing                      | 15 FDC-S XDR-*Ab*                                                                    | No synergy found                                                                                            | ![](images/red_synergy.png){width="35" height="35"}    |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Yamano, 2020 [@yamano2020]                     | AVI, SUL, MER, AMK                    | Checkerboard                                           | 2-FDC-R-PER-*Ab*                                                                     | Synergy for AVI and SUL                                                                                     | ![](images/green_synergy.png){width="35" height="35"}  |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Bianco, 2022 [@bianco2022]                     | TAZ, AVI, VAB, REL                    | Checkerboard                                           | 39 (9-FDC-R: 4 KPC-*Kp*, 3-NDM-EB and 2 NDM and OXA-23-like-*Ab*)                    | KPC: synergy for AVI, VAB, REL                                                                              | ![](images/yellow_synergy.png){width="35" height="35"} |
|                                                |                                       |                                                        |                                                                                      |                                                                                                             |                                                        |
|                                                |                                       |                                                        |                                                                                      | MBL: very low synergy with TAZ, AVI, REL                                                                    |                                                        |
|                                                |                                       |                                                        |                                                                                      |                                                                                                             |                                                        |
|                                                |                                       |                                                        |                                                                                      | OXA: synergy for TAZ, AVI, VAB, REL in all OXA-48-EB but not for *Ab*                                       |                                                        |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
|                                                |                                       | Time-kill                                              | 4 FDC-S (KPC-3-*Kp*, NDM-1-*Ec*, OXA-23-*Ab*, OXA-48-*Kp*) and 1 FDC-R (KPC-50-*Kp*) | KPC: synergy for AVI, VAB, REL                                                                              | ![](images/yellow_synergy.png){width="35" height="35"} |
|                                                |                                       |                                                        |                                                                                      |                                                                                                             |                                                        |
|                                                |                                       |                                                        |                                                                                      | NDM and OXA-23: no synergy                                                                                  |                                                        |
|                                                |                                       |                                                        |                                                                                      |                                                                                                             |                                                        |
|                                                |                                       |                                                        |                                                                                      | OXA-48: synergy for TAZ and AVI                                                                             |                                                        |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Gopikrishnan, 2023 [@gopikrishnan2023]         | ZID and AVI                           | BMD MIC and molecular simulation                       | 52 (13 FDC-R) CRAB (OXA‐23, 24, and 58)                                              | Inhibitory activity of FDC+ZID better than monotherapy                                                      | ![](images/green_synergy.png){width="35" height="35"}  |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Huband, 2024 [@huband2023]                     | SUL                                   | BMD MIC                                                | 66 *Ab*                                                                              | Negative                                                                                                    | ![](images/red_synergy.png){width="35" height="35"}    |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
|                                                | DUR                                   |                                                        |                                                                                      | Positive                                                                                                    | ![](images/green_synergy.png){width="35" height="35"}  |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
|                                                | SUL-DUR                               |                                                        |                                                                                      | Positive (stronger than only with DUR)                                                                      | ![](images/green_synergy.png){width="35" height="35"}  |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Kobic, 2022 [@kobic2022]                       | SUL and TGC                           | Time-kill                                              | 1 FDC-S XDR *Ab*                                                                     | Only synergy for FDC+SUL+TGC                                                                                | ![](images/yellow_synergy.png){width="35" height="35"} |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Wong, 2024 [@wong2024]                         | SUL, AVI                              | \-                                                     | 2 FDC-S Ab and *A. lwoffii* (NDM-1 producers)                                        | Exposure to FDC+SUL or FDC+AVI led to the selection of FDC-R strains                                        | ![](images/red_synergy.png){width="35" height="35"}    |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| You, 2025 [@you2025]                           | \-                                    | AI                                                     | 1 XDR *Ab*                                                                           | FDC+A-S and FDC+PM-B+RIF were pinpointed (93.89 ± 5.95% and 92.23 ± 11.89% inhibition)                      | ![](images/red_synergy.png){width="35" height="35"}    |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
|                                                | A-S, PM-B+RIF                         | Checkerboard                                           | 4 *Ab*                                                                               | FDC+PM-B+RIF showed synergy but FDC+A-S antagonism                                                          | ![](images/yellow_synergy.png){width="35" height="35"} |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Bianco, 2022 [@bianco2022]                     | CZA                                   | Gradient diffusion strip crossing                      | 4 KPC (1 FDC-R) + VIM-EB,                                                            | No synergy                                                                                                  | ![](images/red_synergy.png){width="35" height="35"}    |
|                                                |                                       |                                                        |                                                                                      |                                                                                                             |                                                        |
|                                                |                                       |                                                        | 4 NDM (1 FDC-R) + OXA-48 like-EB and 2 (both FDC-S)  VIM + OXA-48 like-EB            |                                                                                                             |                                                        |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Göpel, 2024 [@göpel2024]                       | ATM                                   | Checkerboard                                           | 20 NDM-*Ent. cloacae*                                                                | Synergy found                                                                                               | ![](images/green_synergy.png){width="35" height="35"}  |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Bianco, 2022 [@bianco2022a]                    | CZA, MEV, IMI, and AMK                | Gradient diffusion strip crossing                      | 6 KPC-*Kp* (3 FDC-R and 3 S)                                                         | Synergy for CZA (synergy rate of 67%)                                                                       | ![](images/green_synergy.png){width="35" height="35"}  |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Boattini, 2022 [@boattini2023]                 | CZA                                   | Gradient diffusion strip crossing                      | 2-VIM*-Pa* and 3 NDM-*Kp*                                                            | Synergy in 1 NDM-*Kp* and only additive effects in 1 NDM-*Kp* and 1 VIM-*Pa*                                | ![](images/yellow_synergy.png){width="35" height="35"} |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Moon, 2023 [@moon2023]                         | AVI                                   | Double-disk assay                                      | 1 FDC-R *Kp*                                                                         | AVI enhanced the activity of FDC                                                                            | ![](images/green_synergy.png){width="35" height="35"}  |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Daoud, 2023 [@daoud2023]                       | AVI, TAZ, SUL, CA, DPA, PMBN          | Checkerboard                                           | 34 *Kp*                                                                              | Synergy with AVI (highest), TAZ, SUL, CA AND PMBN                                                           | ![](images/yellow_synergy.png){width="35" height="35"} |
|                                                |                                       |                                                        |                                                                                      |                                                                                                             |                                                        |
|                                                |                                       |                                                        |                                                                                      | DPA: non-significant improvement                                                                            |                                                        |
|                                                |                                       |                                                        |                                                                                      |                                                                                                             |                                                        |
|                                                |                                       |                                                        |                                                                                      | FDC+AVI+DPA: significant reduction                                                                          |                                                        |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
|                                                | AVI, PMBN                             | Time-kill                                              | 4 *Kp*                                                                               | FDC+AVI enabled the killing of the bacteria earlier with a lower concentration of FDC                       | ![](images/green_synergy.png){width="35" height="35"}  |
|                                                |                                       |                                                        |                                                                                      |                                                                                                             |                                                        |
|                                                |                                       |                                                        |                                                                                      | FDC+AVI+PMBN: bacterial killing at lower concentrations of FDC and less time than FDC+AVI                   |                                                        |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Daoud, 2023 [@daoud2023]                       | AVI, DPA, ATM                         | Checkerboard                                           | 1 FDC-R *Kp*                                                                         | FDC+AVI: no synergy                                                                                         | ![](images/yellow_synergy.png){width="35" height="35"} |
|                                                |                                       |                                                        |                                                                                      |                                                                                                             |                                                        |
|                                                |                                       |                                                        |                                                                                      | FDC+DPA: synergy                                                                                            |                                                        |
|                                                |                                       |                                                        |                                                                                      |                                                                                                             |                                                        |
|                                                |                                       |                                                        |                                                                                      | FDC+AVI+(ATM or DPA): synergy                                                                               |                                                        |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Granata, 2025 [@granata2025]                   | IMR                                   | Gradient diffusion strip crossing                      | 3 FDC-S (2 IMP-13 and 1 VIM-2-*Pa*)                                                  | Synergy in 2 IMP-13-*Pa* (not in VIM-2-*Pa)*                                                                | ![](images/yellow_synergy.png){width="35" height="35"} |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Ferretti, 2024 [@ferretti2024]                 | IMI                                   | Minimum biofilm bactericidal concentration (≈ BMD MIC) | 5 FDC-S *Pa*                                                                         | Synergistic bactericidal activity in all tested strains and synergistic eradicating activity in one isolate | ![](images/yellow_synergy.png){width="35" height="35"} |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| El Haj, 2024 [@elhaj2024]                      | COL                                   | *In vitro* pharmaco ynamic model                       | 2 FDC-S *Pa*                                                                         | COL improved FDC efficacy against biofilms                                                                  | ![](images/green_synergy.png){width="35" height="35"}  |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Schilling, 2024 [@schilling2024]               | VAN                                   | Gradient diffusion strip crossing                      | 2 FDC-S *Pa*                                                                         | Indifferent                                                                                                 | ![](images/red_synergy.png){width="35" height="35"}    |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Wang, 2023 [@wang2023]                         | CBS                                   | BMD MIC                                                | *Pa* and *B. cepacia*                                                                | Synergy found                                                                                               | ![](images/green_synergy.png){width="35" height="35"}  |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
|                                                |                                       | Checkerboard and time-kill                             | *Pa*                                                                                 | Synergy found                                                                                               | ![](images/green_synergy.png){width="35" height="35"}  |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
|                                                |                                       | *In vivo* model                                        | *Pa*                                                                                 | FDC-CBS significantly increased survival                                                                    | ![](images/green_synergy.png){width="35" height="35"}  |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Biagi, 2020 [@biagi2020]                       | LEV, MIN, PM-B, SXT                   | Time-kill                                              | 9-FDC-S *S. maltophilia*                                                             | Synergy found (44% LEV, 67% MIN, 56% PM-B and 67% SXT)                                                      | ![](images/green_synergy.png){width="35" height="35"}  |
+------------------------------------------------+---------------------------------------+--------------------------------------------------------+--------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+

: **Table 1**. Summary of cefiderocol in vitro synergisms. **Molecules** (in alphabetical order) AMK: amikacin, A-S: ampicillin-sulbactam, ATM: aztreonam, AVI: avibactam, CA: clavulanic acid, CBS: colloidal bismuth citrate, CIP: ciprofloxacin, COL: colistin, CZA: ceftazidime-avibactam, DPA: dipicolinic acid, DUR: durlobactam, ERA: eravacycline, FDC: cefiderocol, FOS: fosfomycin, IMI: imipenem, IMR: imipenem-relebactam, LEV: levofloxacin, MER: meropenem, MEV: meropenem-vaborbactam, MIN: minocycline, NAC: nacubactam, OMA: omadacycline, PM-B: polymyxin B, PMBN: polymyxin B nonapeptide, P–T: piperacillin-tazobactam, REL: relebactam, RIF: rifampicin, SUL: sulbactam, SXT: cotrimoxazole, TAN: taniborbactam, TAZ: tazobactam, TGC: tigecycline, TOL-TAZ: ceftolozane-tazobactam, VAB: vaborbactam, VAN: vancomycin, XER: xeruborbactam and ZID: zidebactam. **Methods and isolates** (in alphabetical order) Ab: Acinetobacter baumannii complex, AI: artificil intelligence, BMD MIC: broth microdilution minimal inhibitory concentration, CRAB: carbapenem-resistant *Acinetobacter baumannii complex*, CRE: carbapenem-resistant Enterobacterales, EB: Enterobacterales, Ec: *Escherichia coli*, MBL: metallo ß-lactamase, Pa: *Pseudomonas aeruginosa*, Kp: *Klebsiella pneumoniae*, R: resistant and S: susceptible. **Results**: green: positive synergy, red: no synergy and yellow: variable synergy.

+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **Author, year**                     | **Type of study** | **Infection type**                       | **Pathogen(s)**                          | **Number of patients treated with cefiderocol** | **Combination therapies**                   | **Microbiological outcome** | **Clinical outcome**                                                                                                                                              |
+======================================+===================+==========================================+==========================================+=================================================+=============================================+=============================+===================================================================================================================================================================+
| Bassetti, 2020 [@bassetti2021]       | Clinical trial    | LRTI, BSI, cUTI                          | CRAB, *Kp*, *Pa*, SMAL                   | 80                                              | TGC, FOS, AMK, A-S, CIP, COL, GEN, LEV, P-T | Eradication                 | Clinical cure                                                                                                                                                     |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 66 (83%)                                  |                                             | Mono: 32%                   | Mono: 53%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 14 (18%)                                 |                                             | Combo: 29%                  | Combo: 50%                                                                                                                                                        |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             | P=NS                        | P=NS                                                                                                                                                              |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Dalfino, 2023 [@dalfino2023]         | P                 | VAP                                      | CRAB                                     | 40                                              | FOS, aerosolized COL                        | N/A                         | Clinical cure                                                                                                                                                     |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 19 (48%)                                  |                                             |                             | Mono: 18%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 21 (53%)                                 |                                             |                             | Combo: 36%                                                                                                                                                        |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | P = N/A                                                                                                                                                           |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Buonomo, 2024 [@buonomo2024]         | P                 | VAP, BSI, CLABSI                         | CRAB                                     | 23                                              | A-S, FOS, TGC                               | N/A                         | Clinical cure                                                                                                                                                     |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 11 (48%)                                  |                                             |                             | Mono: 56%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo:12 (52%)                                  |                                             |                             | Combo: 44%                                                                                                                                                        |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | P=NS                                                                                                                                                              |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Giacobbe, 2024 [@giacobbe2024]       | P                 | LRTI, BSI, SSTI, cIAI                    | CRAB, *Pa, E*, SMAL                      | 200                                             | FOS, TGC, A-S, COL, AGs                     | N/A                         | N/A                                                                                                                                                               |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 101(51%)                                  |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo 99 (50%)                                  |                                             |                             |                                                                                                                                                                   |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Falcone, 2022 [@falcone2022]         | R                 | BSI, VAP                                 | CRAB                                     | 47                                              | TGC, FOS, ERT, M-V, A-S                     | Failure                     | N/A                                                                                                                                                               |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 15 (32%)                                  |                                             | Mono 40%                    |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 32 (68%)                                 |                                             | Combo: 6%                   |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             | P \< 0.01                   |                                                                                                                                                                   |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Mazzitelli, 2023 [@mazzitelli2023]   | R                 | BSI, LRTI, cIAI, cUTI                    | CRAB                                     | 60                                              | MER, TGC, FOS                               | Cure                        | Clinical cure                                                                                                                                                     |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 30 (50%)                                  |                                             | Mono: 50%                   | Mono: 33%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 30 (50%)                                 |                                             | Combo: 37%                  | Combo: 53%                                                                                                                                                        |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             | P = 0.03                    | P = NS                                                                                                                                                            |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Russo, 2023 [@russo2023]             | R                 | bacteriemic VAP                          | CRAB                                     | 19                                              | TGC, FOS, TMP/SMX, A-S                      | N/A                         | 30-day survival higher for cefiderocol-based regimens (HR 0.34, 95% CI 0.18–0.56; P \< 0.001) and cefiderocol + fosfomycin (HR 0.22, 95% CI 0.1–0.55; P \< 0.001) |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 0 (0%)                                    |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 19 (100%)                                |                                             |                             |                                                                                                                                                                   |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Bavaro, 2023 [@bavaro2023]           | R                 | BSI                                      | CRAB                                     | 43                                              | FOS, A-S                                    | Resistance development      | 30-day mortality similar in mono vs. combo                                                                                                                        |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 16 (37%)                                  |                                             | Mono: 13%                   | (HR = 0.81, 95% CI 0.39–1.66) and lower for cefiderocol + fosfomycin (HR = 0.43, 95% CI 0.22–0.81)                                                                |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 27 (63%)                                 |                                             | Combo: 0%                   |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             | P = N/A                     |                                                                                                                                                                   |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Piccica, 2023 [@piccica2023]         | R                 | BSI, VAP, cIAI, cUTI                     | CRAB, *Kp*, *Pa*                         | 142                                             | FOS, COL                                    | Cure                        | Clinical cure                                                                                                                                                     |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 70 (49%)                                  |                                             | Mono: 87%                   | Mono: 58%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 72 (51%)                                 |                                             | Combo: 60%                  | Combo: 50%                                                                                                                                                        |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             | P = N/A                     | 30-day mortality                                                                                                                                                  |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Mono: 36%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Combo: 40%                                                                                                                                                        |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | P=NS                                                                                                                                                              |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Palermo, 2023 [@palermo2023]         | R                 | HAP, BSI, cUTI, cIAI, SSTI               | CRAB, *Kp*, *Pa*                         | 41                                              | FOS, COL                                    | Cure                        | Clinical cure                                                                                                                                                     |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 31 (76%)                                  |                                             | Mono: 87%                   | Mono: 58%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 10 (24%)                                 |                                             | Combo: 60%                  | Combo: 50%                                                                                                                                                        |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             | P = N/A                     | 30-day mortality                                                                                                                                                  |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Mono: 36%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Combo: 40%                                                                                                                                                        |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | P = NS                                                                                                                                                            |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Calò, 2023 [@calò2023]               | R                 | LRTI, CLABSI                             | CRAB                                     | 40                                              | A-S, FOS, TGC, AMK                          | Failure                     | Clinical cure                                                                                                                                                     |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 29 (73%)                                  |                                             | Mono: 14%                   | Mono: 42%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 11 (28%)                                 |                                             | Combo: 0%                   | Combo: 64%                                                                                                                                                        |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             | P = N/A                     | 30-day mortality                                                                                                                                                  |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Mono: 52%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Combo: 46%                                                                                                                                                        |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | P = NS                                                                                                                                                            |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Giannella, 2023 [@giannella2023]     | R                 | VAP, BSI, CLABSI                         | CRAB                                     | 147                                             | FOS, COL, TGC, MER, A-S                     | N/A                         | Clinical cure                                                                                                                                                     |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 49 (33%)                                  |                                             |                             | Mono: 61%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 98 (67%)                                 |                                             |                             | Combo: 49%                                                                                                                                                        |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | 28-day survival                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Mono: 53%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Combo: 41%                                                                                                                                                        |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | P = N/A                                                                                                                                                           |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Gavghan, 2023 [@gavaghan2023]        | R                 | LRTI                                     | CRAB, *Pa*                               | 24                                              | TGC, GEN, COL, TOB, MIN                     | N/A                         | 28-day mortality                                                                                                                                                  |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 16 (67%)                                  |                                             |                             | Mono: 25%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 8 (33%)                                  |                                             |                             | Combo: 0%                                                                                                                                                         |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Frattari, 2024 [@frattari2024]       | R                 | Sepsis                                   | CRAB                                     | 36                                              | N/A                                         | N/A                         | 30 day mortality                                                                                                                                                  |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono:16 (44%)                                   |                                             |                             | Mono: 56%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo 22 (61%)                                  |                                             |                             | Combo: 50%                                                                                                                                                        |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Oliva, 2024 [@oliva2024]             | R                 | BSI, VAP, HAP, CLABSI,                   | CRAB                                     | 50                                              | A-S, FOS, TGC, MER                          | N/A                         | N/A                                                                                                                                                               |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 14 (28)                                   |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 36 (72%)                                 |                                             |                             |                                                                                                                                                                   |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| El Ghali, 2024 [@elghali2024]        | R                 | BSI, VAP, HAP, SSTI, cIAI, cUTI, BJI     | CRAB, *Pa*, *Kp*                         | 112                                             | COL, CZA-AVI, AGs, ERAV, IMI-REL, CEP, A-S  | Cure                        | 30-day mortality                                                                                                                                                  |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 39 (35%)                                  |                                             | Mono: 78%                   | Mono: 18%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 73 (65%)                                 |                                             | Combo: 82%                  | Combo: 82%                                                                                                                                                        |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Clinical cure                                                                                                                                                     |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Mono: 64%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Combo: 35%                                                                                                                                                        |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Clancy, 2024 [@clancy2024]           | R                 | LRTI, SSTI, BSI, cUTI, cIAI, BJI, other  | CRAB, *Pa,* E*,* SMAL, other             | 244                                             | N/A                                         | N/A                         | N/A                                                                                                                                                               |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 130 (53%)                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 114 (47%)                                |                                             |                             |                                                                                                                                                                   |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Russo, 2024 [@russo2024]             | R                 | VAP, BSI, CLABSI, other                  | CRAB                                     | 54                                              | FOS                                         | N/A                         | Clinical cure                                                                                                                                                     |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 54 (100%)                                |                                             |                             | Combo: 77%                                                                                                                                                        |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Balandin, 2024 [@balandín2024]       | R                 | LRTI, SSTI, cIAI, cUTI, BSI, CLABSI, BJI | *Pa*, E, *Kp*, CRAB, SMAL                | 63                                              | COL                                         | N/A                         | N/A                                                                                                                                                               |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo; 33 (52%)                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 30 (48%)                                  |                                             |                             |                                                                                                                                                                   |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Souege, 2024 [@soueges2025]          | R                 | LRTI, BSI, cUTI                          | *Pa*, E, other                           | 114                                             | N/A                                         | N/A                         | 28-day mortality                                                                                                                                                  |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo 58 (51%)                                  |                                             |                             | Mono: 34%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 56 (49%)                                  |                                             |                             | Combo: 41%                                                                                                                                                        |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Clinical cure                                                                                                                                                     |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Mono: 55%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Combo: 52%                                                                                                                                                        |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Gatti, 2021 [@gatti2022]             | Case series       | BSI, VAP                                 | CRAB                                     | 13                                              | A-S, FOS, COL                               | Failure                     | 30-day mortality                                                                                                                                                  |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 3 (23%)                                   |                                             | Mono: 1/3 (33%)             | Mono: 2/3 (66%)                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 10 (67%)                                 |                                             | Combo: 5/10 (50%)           | Combo: 2/10 (20%)                                                                                                                                                 |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Rando, 2021 [@rando2021]             | Case series       | VAP                                      | CRAB                                     | 13                                              | COL, FOS                                    | N/A                         | Clinical cure                                                                                                                                                     |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 8 (62%)                                   |                                             |                             | Mono: 75%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 5 (39%)                                  |                                             |                             | Combo: 20%                                                                                                                                                        |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | P = N/A                                                                                                                                                           |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Corcione, 2022 [@corcione2022]       | Case series       | VAP                                      | CRAB, SMAL, *Kp*                         | 18                                              | TGC, aerosolized COL                        | Failure                     | Clinical cure:                                                                                                                                                    |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 4 (22%)                                   |                                             | Mono: 25%                   | Mono: 75%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 14 (78%)                                 |                                             | Combo: 21%                  | Combo: 64%                                                                                                                                                        |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | 30-day mortality                                                                                                                                                  |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Mono: 25%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Combo: 29%                                                                                                                                                        |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | P = N/A                                                                                                                                                           |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Smoke, 2022 [@smoke2023]             | Case series       | BSI, LRTI                                | CRAB                                     | 11                                              | POL                                         | N/A                         | Clinical cure                                                                                                                                                     |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 3 (28%)                                  |                                             |                             | Mono: 2/3 (66%)                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 8 (72%)                                   |                                             |                             | Combo: 2/9 (22%)                                                                                                                                                  |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | 30-day mortality                                                                                                                                                  |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Mono 1/3 (33%)                                                                                                                                                    |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Combo 1/9 (11%)                                                                                                                                                   |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Wicky, 2023 [@wicky2023]             | Case series       | BSI                                      | CRAB, *Pa*, SMAL                         | 16                                              | COL, FOS, TGC                               | N/A                         | Clinical cure                                                                                                                                                     |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 11 (69%)                                  |                                             |                             | Mono: 82%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 5 (31%)                                  |                                             |                             | Combo: 80%                                                                                                                                                        |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | P = N/A                                                                                                                                                           |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| De la Fuente, 2023 [@delafuente2023] | Case series       | HAP, VAP                                 | *Pa*, *Burkholderia cepacia*, *KpI*,SMAL | 13                                              | COL, CIP, LEV, CAZ, MER                     | Cure                        | Clinical cure                                                                                                                                                     |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 6 (46%)                                   |                                             | Mono: 13/13 (100%)          | Mono: 92%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 7 (54%)                                  |                                             | Combo: 6/7 (86%)            | Combo: 86%                                                                                                                                                        |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | P = N/A                                                                                                                                                           |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | 28-day mortality                                                                                                                                                  |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Mono: 8%                                                                                                                                                          |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Combo: 28%                                                                                                                                                        |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | P = N/A                                                                                                                                                           |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Meschiari, 2021 [@meschiari2021]     | Case series       | VAP, HAP, cIAI, EVD-menigitis, BSI       | *Pa*                                     | 17                                              | Aerosolized COL, FOS, CAZ-AVI, AMK          | Failure                     | Clinical failure day 7                                                                                                                                            |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 3 (18%)                                   |                                             | Mono: 2/3 (66%)             | Mono: 28%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 14 (82%)                                 |                                             | Combo: 2/14 (14%)           | Combo: 0%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | P = N/A                                                                                                                                                           |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Fendian, 2023 [@fendian2023]         | Case series       | VAP, BSI                                 | CRAB, *Pa*, *Achromobacter xylooxidans*  | 10                                              | COL, TGC, LEV, CAZ-AVI, CEP                 | Microbiological resistance  | Clinical failure day 7                                                                                                                                            |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 3 (33%)                                   |                                             | Mono: 1/3 (33%)             | Mono: 0%                                                                                                                                                          |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 7 (67%)                                  |                                             | Combo: 1/7 (14%)            | Combo: 14%                                                                                                                                                        |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | P = N/A                                                                                                                                                           |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | 90-day mortality                                                                                                                                                  |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Mono: 33%                                                                                                                                                         |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Combo: 50%                                                                                                                                                        |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | P = N/A                                                                                                                                                           |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Campogiani, 2023 [@campogiani2023]   | Case series       | BSI, VAP, cUTI, IAI                      | CRAB                                     | 11                                              | COL, TGC                                    | Breakthrough infections     | Early clinical improvement                                                                                                                                        |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 3/11 (27%)                                |                                             | Mono: 0/3 (0%)              | Mono: 2/3 (66.67%)                                                                                                                                                |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 8/11 (73%)                               |                                             | Combo: 1/8 (12.5%)          | Combo: 6/8 (75%)                                                                                                                                                  |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             | P = N/A                     | P = N/A                                                                                                                                                           |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             | Microbiological relapse:    | Clinical cure                                                                                                                                                     |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             | Mono: 0/3 (0%)              | Mono: 2/3 (66.67%)                                                                                                                                                |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             | Combo: 0/8 (0%)             | Combo 6/8 (75%)                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             | P = N/A                     | P = N/A                                                                                                                                                           |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Overall 30-day mortality                                                                                                                                          |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Mono: 1/3 (33.3%)                                                                                                                                                 |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | Combo: 2/8 (25%)                                                                                                                                                  |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | P = N/A                                                                                                                                                           |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Persuad, 2024 [@persaud2024]         | Case series       | HAP, VAP                                 | *Pa*, E                                  | 15                                              | COL, CAZ-AVI, AMK, POL                      | Cure                        | 30-day mortality                                                                                                                                                  |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 3/15 (20%)                                |                                             | Mono: 2/3 (66.6%)           | Mono: 1/3 (33%)                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 12/15 (80%)                              |                                             | Combo: 7/12 (58%)           | Combo: 3/12 (25%)                                                                                                                                                 |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             | P = N/A                     | P = N/A                                                                                                                                                           |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             | Resistance:                 |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             | Mono: 0/3 (0%)              |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             | Combo: 1/12 (8%)            |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             | P = N/A                     |                                                                                                                                                                   |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Travi, 2024 [@travi2024]             | Case series       | VAP, BSI, BJI                            | CRAB (100% NDM)                          | 12                                              | COL                                         | N/A                         | Clinical cure day-7:                                                                                                                                              |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Mono: 2/12 (17%)                                |                                             |                             | Mono: 1/2 (50%)                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          | Combo: 10/12 (83%)                              |                                             |                             | Combo: 9/10 (90%)                                                                                                                                                 |
|                                      |                   |                                          |                                          |                                                 |                                             |                             |                                                                                                                                                                   |
|                                      |                   |                                          |                                          |                                                 |                                             |                             | P = N/A                                                                                                                                                           |
+--------------------------------------+-------------------+------------------------------------------+------------------------------------------+-------------------------------------------------+---------------------------------------------+-----------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------+

: **Table 2.** Summary of cefiderocol combination therapies in human studies. **Molecules** (in alphabetical order) AMK: amikacin, A–S: ampicillin-sulbactam, CEP: cefepime, CIP: ciprofloxacin, COL: colistin, CAZ: ceftazidime, CZA-AVI: ceftazidime-avibactam, FOS: fosfomycin, LEV: levofloxacin, MER: meropenem, MIN: minocycline, M-V: meropenem-vaborbactam, P–T: piperacillin-tazobactam, TMP/SMX: trimethoprim/sulfamethoxazole, TGC: tigecycline, TOB: tobramycin, AGs: aminoglycosides, ERAV: eravacycline, IMI-REL: imipenem/cilistatin/releabactam. POL: polymixin. **Isolates** (in alphabetical order) CRAB: carbapenem-resistant *Acinetobacter baumannii complex*, Pa: *P. aeruginosa*; Kp: *K. pneumoniae*; E: Enterobacteriales; SMAL: *Stenotrophomonas maltophilia*; XDR: extensively-drug resistant. **Type of study and conditions** P: prospective study; R: retrospective study; Combo: combination. BSI: bloodstream infection; CLABSI: central line associated BSI; LRTI: lower respiratory tract infections; SSTI: skin and soft tissue infections; cIAI: complicated intra-abdominal infection; cUTI: complicated urinary tract infection; EVD extra ventricular drainage; HAP: hospital acquired pneumonia; VAP: Ventilator-Associated Pneumonia, BJI: bone and joint infections. **Results** NS: non-significant; N/A: *P values* not reported or calculated by the authors are reported.
:::

# Exploratory Meta-analysis

## Materials and methods

Randomized controlled trials (RCTs) and observational cohort studies enrolling at least 25 patients were included. Case series, case reports, and studies with fewer than 25 total participants were excluded from the analysis. Details regarding the search strategy, screening and data extraction process are provided in the main manuscript.

## Quality of evidence

Quality assessment was performed using the Cochrane risk-of-bias tool for RCTs and the Newcastle-Ottawa Scale for observational cohort studies.

| Criteria                                         | **Evaluation**    |
|--------------------------------------------------|-------------------|
| Randomisation process                            | \- High risk      |
| Deviations from Intended interventions Signaling | \- High risk      |
| Missing outcomes                                 | \- Low risk       |
| Measurement of outcome                           | \- Low risk       |
| Selection of reported results                    | \- Some concernes |
| **Overall**                                      | \- Some concernes |

: **Table S1**: Robins-2 assessment of risk of bias– Clinical trial, Bassetti et al 2020 [@bassetti2021]. Note that risk of Bias is assessed focusing on the comparison between cefiderocol monotherapy and combination therapy and not the primary endpoint of the study.

+--------------------------------------+----------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+
| **Criteria**                         | **Acceptable**                                                                                                             | **Unacceptable**                                                                            |
|                                      |                                                                                                                            |                                                                                             |
|                                      | **(star awarded)**                                                                                                         | **(star not awarded)**                                                                      |
+======================================+============================================================================================================================+=============================================================================================+
| Representativeness of exposed cohort | Truly representative OR somewhat representative                                                                            | No description                                                                              |
+--------------------------------------+----------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+
| Selection of non-exposed cohort      | Drawn from the same community as the exposed cohort                                                                        | Drawn from a different source OR no description of the derivation of the non-exposed cohort |
+--------------------------------------+----------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+
| Ascertainment of exposure            | Secure records or directly measured                                                                                        | Self-report OR unclear                                                                      |
+--------------------------------------+----------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+
| Comparability                        | -   Adjusted for age, sex, comorbidities.                                                                                  | No adjustment                                                                               |
|                                      | -   Adjusted for known colonization or source control, or previous antibiotic therapy or time from diagnosis to antibiotic |                                                                                             |
+--------------------------------------+----------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+
| Outcome of interest                  | Secure records or directly measured                                                                                        | Self-report OR unclear                                                                      |
+--------------------------------------+----------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+
| Adequacy of follow-up                | Adjusted for missing data or follow-up \> 14 days.                                                                         | No statement regarding missing data. No follow-up after end of therapy                      |
+--------------------------------------+----------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+

: **Table S2**: Risk of bias: low 6-7 stars, moderate 4-5 stars, high 1-3 stars. Note that risk of Bias is assessed focusing on the comparison between cefiderocol monotherapy and combination therapy that, in most of the cases, is not the primary outcome of interest of the studies.

## Analysis

A meta-analysis was conducted using random-effects models with the restricted maximum-likelihood (REML) estimator to account for between-study variability. The analysed outcomes were 30-day all-cause mortality, clinical and microbiological cure in patients treated with cefiderocol combination therapy versus monotherapy. Effect sizes were calculated as odds ratios (ORs) with 95% confidence intervals (CIs). When available, adjusted effect sizes were pooled using the inverse variance method. In the absence of adjusted estimates, crude odds ratios were calculated and included in the analysis.

A 95% prediction interval was also displayed to estimate the range in which the true effect of a new study is expected to lie. Heterogeneity across studies was assessed using the Chi-squared test (with a p-value \< 0.1 indicating substantial heterogeneity) and the I² statistic (with values \> 50% considered indicative of moderate to high heterogeneity).

A subgroup analysis was performed based on the type of infection, distinguishing between CRAB infections only and mixed MDR infections. To assess whether treatment effects differed significantly between subgroups, a Q-test for subgroup differences was performed. With two subgroups, this test is based on one degree of freedom. A p-value \< 0.05 was considered indicative of a significant difference in effect estimates.

Potential publication bias was evaluated through contour-enhanced funnel plots, incorporating significance contours at *p* \< 0.1, *p* \< 0.05, and *p* \< 0.01, as shown in the plot legends.Egger’s test for funnel plot asymmetry was not performed, as none of the pooled analyses included 10 or more studies. For the same reason, the trim and fill method was not applied.

Influence analysis was conducted to evaluate the robustness of the results. Baujat plots were used to identify studies with the greatest contribution to heterogeneity and effect size, and leave-one-out analyses were performed to assess the influence of individual studies on the overall pooled estimate (results not shown, available on github).

All analyses were conducted using R software (version 4.4.3). The meta and dmetar packages were primarily used for meta-analysis calculations and sensitivity analysis.

## **Data availability**

Data and analysis are available at: <https://github.com/mat194/Cefiderocol-Meta-analysis>

## Results

### **Does cefiderocol combination therapy improve 30 days mortality compared to monotherapy?**

![](images/clipboard-384120512.png){fig-align="center"}

A total of nine retrospective studies published between 2022 and 2024 were included in the meta-analysis, comprising both monocentric and multicentric designs from Italy (n = 6), the USA (n = 1), France (n = 1), and an international collaboration (n = 1). Only one study [@piccica2023] provided an adjusted effect estimate using a propensity score inverse probability weighting method (aOR 1.11, 95% CI 0.63–1.96). The remaining studies relied on univariate analyses. CRAB was the most frequently targeted pathogen, although several studies also included broader MDR organisms.

The test for subgroup differences was not statistically significant, indicating no strong evidence of differential treatment effect between the subgroups.

The influence analysis indicated that no single study disproportionately affected the overall pooled estimate or heterogeneity. The Baujat plot showed that onely *Falcone, 2022* [@falcone2022] contributed most to heterogeneity, while *Piccica, 202*3 [@piccica2023] had the greatest influence on the pooled result. However, leave-one-out sensitivity analysis confirmed the stability of the overall effect estimate, with no major change in heterogeneity (I² remained 0% in all iterations).

![](images/clipboard-4124015486.png){fig-align="center"}

The contour-enhanced funnel plot does not reveal clear evidence of publication bias. The distribution of studies appears relatively symmetrical around the central effect estimate, and most points fall within non-significant regions, suggesting that any observed asymmetry is unlikely to be due to selective reporting of statistically significant results.

### **Does cefiderocol combination therapy improve clinical cure compared to monotherapy?**

![](images/clipboard-4070756505.png)

None of the included studies reported adjusted effect estimates; all results were derived from univariate analyses. The analysis includes one randomized clinical trial, two prospective cohort studies, and six retrospective observational studies.

The influence analysis revealed that no single study had a disproportionate impact on the pooled effect estimate, although a few studies contributed more to heterogeneity or had a slightly higher influence. According to the Baujat plot, *Dalfino, 2023* [@dalfino2023] showed the highest contribution to heterogeneity, while *Giannella, 2023* [@giannella2023] had the greatest influence on the pooled result.

The test for subgroup differences was not statistically significant, suggesting no clear evidence of a differential treatment effect between the two infection categories.

Leave-one-out analysis confirmed the robustness of the meta-analytic findings. Omitting individual studies led to minimal shifts in the pooled odds ratio, and none of the exclusions resulted in a statistically significant change. Heterogeneity remained low to moderate (I² range: 0% to 43%) throughout, indicating consistent findings across studies.

![](images/clipboard-3145531308.png){fig-align="center"}

### **Does cefiderocol combination therapy improve microbiological cure compared to monotherapy?**

![](images/clipboard-135960318.png)

None of the included studies reported adjusted effect estimates; all outcomes were based on univariate comparisons. The analysis includes one randomized clinical trial, and four retrospective observational studies.

The influence analysis showed that the overall pooled estimate was robust, with no single study exerting a disproportionate influence on the meta-analytic result. The Baujat plot identified *Mazzitelli, 2023* as the most influential study on the pooled effect size, followed by *El Ghali, 2024* [@elghali2024] and *Palermo, 2023* [@palermo2023]. However, the contribution of all studies to overall heterogeneity remained minimal.

The test for subgroup differences yielded a statistically significant result, suggesting a potential difference in treatment effect between the CRAB and mixed infection groups. However, this result must be interpreted with caution. As noted in the Cochrane Handbook for Systematic Reviews of Interventions, statistical tests for subgroup differences can yield spurious significance when the number of studies is small, and power to detect true differences is generally low. With only two and three studies in the respective subgroups, the observed significance may reflect random variation rather than a true differential effect.

Leave-one-out sensitivity analysis confirmed the stability of the results. Omitting any single study did not lead to significant shifts in the pooled odds ratio. Heterogeneity remained low (I² = 0%) throughout all iterations, reinforcing the consistency of findings.

![](images/clipboard-3107019296.png){fig-align="center"}

### References

::: {#refs}
:::
